Table of Contents:
Chapter 1. Executive Summary
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions
2.4 Limitations
Chapter 3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
Chapter 4. Market Dynamics
4.1 Overview
4.2 Drivers
4.3 Restraints
4.4 Opportunities
4.5 Pipeline Analysis
4.5 Macroeconomic Indicators
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Opportunities
Chapter 6. Global Active Pharmaceutical Ingredient for Cancer Market, by Type
6.1 Overview
6.2 Tyrosine kinase inhibitor (Tinib)
6.2.1 Ponatinib
6.2.2 Brigatinib
6.2.3 Ruxolitinib
6.2.4 Erlotinib
6.2.5 Alectinib
6.2.6 Cobimetinib
6.2.7 Neratinib
6.2.8 Osimertinib
6.2.9 Acalabrutinib
6.2.10 Bosutinib
6.2.11 Crizotinib
6.2.12 Axitinib
6.2.13 Sunitinib
6.2.14 Ceritinib
6.2.15 Imatinib
6.2.16 Lapatinib
6.2.17 Afatinib
6.2.18 Cabozantinib
6.2.19 Dasatinib
6.2.20 Ibrutinib
6.2.21 Lenvatinib
6.2.22 Gefitinib
6.2.23 Others
6.3 Proteasome Inhibitors (Parib)
6.3.1 Olaparib
6.3.2 Rucaparib
6.3.3 Niraparib
6.4 BRAF Kinase Inhibitors (rafenib)
6.4.1 Sorafenib
6.4.2 Regorafenib
6.4.3 Vemurafenib
6.4.4 Dabrafenib
6.4.5 Enasidenib
6.4.6 Others
6.5 Phosphatidylinositol 3-kinase Inhibitors (Lisib)
6.5.1 Idelalisib
6.5.2 Copanlisib
6.6 SMO Receptor Antagonists (Degib)
6.6.1 Sonidegib
6.6.2 Vismodegib
6.7 Cyclin Dependent Kinase Inhibitors (Ciclib)
6.7.1 Palbociclib
6.7.2 Ribociclib
6.7.3 Abemaciclib
6.8 Others
Chapter 7. Global Active Pharmaceutical Ingredient for Cancer Market, by Indication
7.1 Overview
7.2 Blood Cancer
7.3 Skin Cancer
7.4 Lungs Cancer
7.5 Breasts Cancer
7.6 Pancreas Cancer
7.7 Others
Chapter 8. Global Active Pharmaceutical Ingredient for Cancer Market, by End User
8.1 Overview
8.2 Pharmaceutical Companies
8.3 Research Organizations
8.4 Others
Chapter 10. Global Active Pharmaceutical Ingredient for Cancer Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Key Development & Strategies
Chapter 12 Company Profiles
12.1 AbbVie
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 Pfizer Inc.
12.3 Boehringer Ingelheim International GmbH
12.4 AstraZeneca
12.5 Novartis AG.
12.6 F. Hoffmann-La Roche AG
12.7 Bayer AG
12.8 Bristol-Myers Squibb Company
12.9 Eisai Co., Ltd
12.10 Johnson & Johnson
12.11 Merck Sharp & Dohme Corp.
12.12 Amgen Inc
12.13 Others
Chapter 13 Appendix
LIST OF TABLES
TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SYNOPSIS, 2020-2027
TABLE 2. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)
TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 7. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 8. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 9. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 11. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 12. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 13. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 14. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 15. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 17. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 18. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 19. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 20. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 21. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 23. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 24. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 25. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 26. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 27. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 28. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 29. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 30. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 31. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 32. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 33. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1. RESEARCH PROCESS
FIGURE 2. SEGMENTATION FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET
FIGURE 3. MARKET DYNAMICS FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET
FIGURE 4. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY TYPE, 2020
FIGURE 5. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY INDICATIONS, 2020
FIGURE 6. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY END USER, 2020
FIGURE 7. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY REGION, 2020
FIGURE 8. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020
FIGURE 9. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020
FIGURE 10. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020
FIGURE 11. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY REGION, 2020
FIGURE 12. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 13. ABBVIE: KEY FINANCIALS
FIGURE 14. ABBVIE: SEGMENTAL REVENUE
FIGURE 15. ABBVIE: GEOGRAPHICAL REVENUE
FIGURE 16. PFIZER INC: KEY FINANCIALS
FIGURE 17. PFIZER INC: SEGMENTAL REVENUE
FIGURE 18. PFIZER INC: GEOGRAPHICAL REVENUE
FIGURE 19. PFIZER INC: KEY FINANCIALS
FIGURE 20. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SEGMENTAL REVENUE
FIGURE 21. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: GEOGRAPHICAL REVENUE
FIGURE 22. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY FINANCIALS
FIGURE 23. ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 24. ASTRAZENECA: GEOGRAPHICAL REVENUE
FIGURE 25. ASTRAZENECA: KEY FINANCIALS
FIGURE 26. NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 27. NOVARTIS AG: GEOGRAPHICAL REVENUE
FIGURE 28. NOVARTIS AG.: KEY FINANCIALS
FIGURE 29. F. HOFFMANN-LA ROCHE AG.: SEGMENTAL REVENUE
FIGURE 30. F. HOFFMANN-LA ROCHE AG.: GEOGRAPHICAL REVENUE
FIGURE 31. F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS
FIGURE 32. BAYER AG: SEGMENTAL REVENUE
FIGURE 33. BAYER AG: GEOGRAPHICAL REVENUE
FIGURE 34. BAYER AG: KEY FINANCIALS
FIGURE 35. BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 36. BRISTOL-MYERS SQUIBB COMPANY: GEOGRAPHICAL REVENUE
FIGURE 37. BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
FIGURE 38. EISAI CO., LTD: SEGMENTAL REVENUE
FIGURE 39. EISAI CO., LTD: GEOGRAPHICAL REVENUE
FIGURE 40. EISAI CO., LTD: KEY FINANCIALS
FIGURE 41. JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 42. JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE
FIGURE 43. JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 44. MERCK SHARP & DOHME CORP.: SEGMENTAL REVENUE
FIGURE 45. MERCK SHARP & DOHME CORP.: GEOGRAPHICAL REVENUE
FIGURE 46. MERCK SHARP & DOHME CORP.: KEY FINANCIALS
FIGURE 47. AMGEN INC: SEGMENTAL REVENUE
FIGURE 48. AMGEN INC: GEOGRAPHICAL REVENUE
FIGURE 49. AMGEN INC: KEY FINANCIALS
